Aditya Spinners manufactures and sells blended synthetic yarns, primarily polyester and viscose, for use in the textile and apparel industries.
The company operates in a highly fragmented, commodity-driven industry with no evidence of pricing power, as reflected by net margins averaging just 2.2% and a recent swing into losses. Low returns on capital (5.6%) suggest the business lacks any durable competitive advantage or scale-based cost edge.
Capital has been largely tied up in working capital and maintenance of aging assets, with significant reliance on unsecured loans from promoters to fund operations. The lack of meaningful dividends or value-creative reinvestment is evidenced by a negative EPS CAGR over the period.
The business succumbed to a slow-motion liquidation as its aging assets and commodity-grade output failed to cover the cost of capital. The observed interest coverage of 0.19 proved fatal when promoter-funded unsecured loans were no longer sufficient to bridge the gap between stagnant revenue and rising regulatory costs. The retrospective restatements and statutory arrears signaled a breakdown in financial control, leading to a permanent impairment of capital as the company became a 'zombie' entity, surviving only to service debt and maintenance capex without ever generating a real return for minority shareholders.
RichFakir rates Aditya Spinners Ltd's business quality as poor — 20/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Aditya Spinners Ltd is trading about 46% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Aditya Spinners Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Aditya Spinners Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →